Project Grant K08HL177427
Award Date 9/15/25
Completion Date 8/31/30
Dollars Obligated $166K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research at New York University School of Medicine to investigate the use of HLA eplet mismatches (EMM) as a biomarker for immunologic risk in heart transplant recipients. The $819,532 award aims to leverage existing datasets and patient cohorts to model the association between EMM and immunoreactivity, which could help guide personalized immunosuppression...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $762,747 project grant to New York University (NYU) to develop engagement protocols for donor family members and healthcare staff during research involving the recently deceased. This research aims to advance the field of xenotransplantation, which uses organs from deceased humans maintained through medical interventions to test novel pharmaceuticals and medical...
- The University of Utah received a $782,289 project grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to develop machine learning models that incorporate donor lung CT images to predict the risk of severe primary graft dysfunction (PGD) in lung transplant recipients. The project aims to leverage a multi-center cohort of lung transplant data to build improved predictive models that fuse donor and recipient clinical data with...
- This Project Grant award of $207,740.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop a machine learning model that can predict permissive human leukocyte antigen (HLA) mismatches for hematopoietic stem cell transplants (HCT) using post-transplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis. The goal is to improve HCT utilization and outcomes for ethnic minority patients who face disparities in donor...
- This federal Project Grant award, valued at $272,226.00, was granted by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The project aims to determine how clinician and scheduling characteristics impact patient outcomes, and explore the moderating effect of patient characteristics on these relationships, for mechanically ventilated adults in intensive care units. The project will conduct a novel secondary analysis utilizing a unique...
- This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to apply state-of-the-art methods to evaluate the effectiveness of mechanical circulatory support (MCS) devices in treating acute myocardial infarction complicated by cardiogenic shock (AMI-CS). The $817,358 award, effective from August 19, 2025 to May 31, 2029, will support the following key activities: Appending individual patient...
- This federal Project Grant award, valued at $158,652 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research into the impact of alveolar macrophage senescence in aged donor lungs on post-lung transplant outcomes. The award, with a start date of September 1, 2025 and an ultimate completion date of August 31, 2030, will be carried out by Duke University's Office of Research Administration Division. The research aims to...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $186,408 to the University of Washington to develop robust models that identify patients at high risk for persistent hypoxemic respiratory failure (HRF). The goal is to improve the ability to distinguish patients with persistent HRF early, which is critical for enrolling the highest-risk patients in clinical trials for new HRF...